<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444846</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-1005-202</org_study_id>
    <nct_id>NCT01444846</nct_id>
  </id_info>
  <brief_title>Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift</brief_title>
  <official_title>Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sound Pharmaceuticals, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sound Pharmaceuticals, Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exposure to loud sounds can cause hearing loss. The purpose of this research study is to
      evaluate potential prevention of temporary changes in hearing that may occur after listening
      to music through an iPod or personal music player. We will measure temporary changes in
      hearing in subjects who listen to music and take either the study drug, SPI-1005, or a
      placebo for 4 days. SPI-1005 is a proprietary preparation of ebselen that allows it to be
      taken by mouth. Ebselen contains the mineral selenium and behaves like Glutathione
      Peroxidase, an enzyme that helps to rid the body of damaging chemicals caused by loud sounds.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Temporary Threshold Shift</measure>
    <time_frame>1 week</time_frame>
    <description>Post-sound exposure pure tone audiometry will be compared with baseline (i.e., immediately pre-sound exposure) testing to determine group mean level hearing threshold shift changes between treated and placebo groups.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Temporary Auditory Threshold Shift</condition>
  <arm_group>
    <arm_group_label>SPI-1005 Low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg SPI-1005, capsule, bid, po, x4d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 Middle Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400mg SPI-1005, capsule, bid, po, x4d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600mg SPI-1005, capsule, bid, po, x4d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0mg SPI-1005, capsule, bid, po, x4d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 Low dose</intervention_name>
    <description>Oral capsules, 200 mg ebselen, twice daily, 4 days</description>
    <arm_group_label>SPI-1005 Low dose</arm_group_label>
    <other_name>200 mg Ebselen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 Middle dose</intervention_name>
    <description>Oral capsules, 400 mg ebselen, twice daily, 4 days</description>
    <arm_group_label>SPI-1005 Middle Dose</arm_group_label>
    <other_name>400 mg Ebselen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 High dose</intervention_name>
    <description>Oral capsules, 600 mg ebselen, twice daily, 4 days</description>
    <arm_group_label>SPI-1005 High Dose</arm_group_label>
    <other_name>600mgEbselen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral capsules, 0 mg ebselen, twice daily, 4 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0 mg Ebselen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects at the time of enrollment.

          -  Each subject will give informed consent to participate in this study and agrees to the
             treatment protocol.

          -  Each subject will be interviewed regarding hearing and health to reveal any history of
             hearing loss, tinnitus, known ear pathology, use of any potentially ototoxic
             medications (i.e. diuretics, minocycline).

          -  Non-occupational sound exposure (e.g., concerts, firearms, fireworks, power tools)
             will be avoided during the 24-hour period preceding baseline testing and throughout
             the duration of the study.

          -  Subjects will have vital signs (i.e., heart rate, blood pressure, respirations,
             temperature) within normal limits upon medical examination.

          -  Subjects must have normal audiologic assessment at baseline consisting of:

          -  Baseline audiometric evaluation confirms that subjects have symmetric hearing with air
             conduction thresholds no worse than 25 decibels of Hearing Loss (dBHL) at frequencies
             between 0.25 to 8 kilo Hertz (kHz) bilaterally.

          -  No significant threshold asymmetry (i.e. greater than 15 dB) between the ears at any
             tested frequency.

          -  No significant air-bone gaps (i.e. greater than 10 dB)

          -  Type A tympanograms bilaterally, defined as a range of -140 to +40 dekaPascals (daPa)
             based on the 90% range for adults (Margolis and Hunter 2000)

        Exclusion Criteria:

          -  â€¢ Subjects with abnormal hearing levels &gt; 25 dBHL at any tested frequency (250, 500,
             1000, 2000, 3000, 4000, 6000 and 8000 Hz) for either ear.

          -  Exposure to any duration of non-occupational high-level sound (e.g., concerts,
             firearms, fireworks, power tools) during the 24 hour period preceding baseline
             audiometric testing as revealed in the subject questionnaire or during the medical
             examination.

          -  Pathology of the external ear discovered upon otoscopic examination.

          -  Pathology of the middle ear revealed by otoscopic examination, abnormal tympanometry,
             or reported history of middle ear problems.

          -  Pathology of the inner ear or auditory nerve as revealed by reported history.

          -  Subject complaints of aural pain, pressure, fullness, or drainage.

          -  Subjects testing positive for pregnancy will be excluded from the study.

          -  Subjects with other medical/health issues that would preclude voluntary participation
             in a drug study may be excluded at the discretion of the Principal Investigator.

          -  Subjects that have previously received any known potentially ototoxic medication. This
             includes, but is not limited to, high dose salicylates (&gt;2 g/day), platinum-based
             chemotherapeutics and aminoglycoside antibiotics, such as streptomycin,
             gentamicin,tobramycin, amikacin, neomycin, and netilmycin.

          -  Subjects that are currently using of any potentially ototoxic medications (i.e.
             diuretics or minocycline).

          -  Subjects that have received any investigational treatment (drug or device) in the six
             months prior to this study.

          -  Subjects exhibiting or self-reporting shortness of breath, wheezing, coughing, or
             hemoptysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>31 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colleen Le Prell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Kil, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sound Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric D Lynch, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sound Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pourbakht A, Yamasoba T. Ebselen attenuates cochlear damage caused by acoustic trauma. Hear Res. 2003 Jul;181(1-2):100-8.</citation>
    <PMID>12855368</PMID>
  </reference>
  <reference>
    <citation>Lynch ED, Gu R, Pierce C, Kil J. Ebselen-mediated protection from single and repeated noise exposure in rat. Laryngoscope. 2004 Feb;114(2):333-7.</citation>
    <PMID>14755214</PMID>
  </reference>
  <reference>
    <citation>Lynch ED, Gu R, Pierce C, Kil J. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res. 2005 Mar;201(1-2):81-9.</citation>
    <PMID>15721563</PMID>
  </reference>
  <reference>
    <citation>Yamasoba T, Pourbakht A, Sakamoto T, Suzuki M. Ebselen prevents noise-induced excitotoxicity and temporary threshold shift. Neurosci Lett. 2005 Jun 3;380(3):234-8. Epub 2005 Feb 1.</citation>
    <PMID>15862892</PMID>
  </reference>
  <reference>
    <citation>Lynch ED, Kil J. Compounds for the prevention and treatment of noise-induced hearing loss. Drug Discov Today. 2005 Oct 1;10(19):1291-8. Review.</citation>
    <PMID>16214673</PMID>
  </reference>
  <reference>
    <citation>Kil J, Pierce C, Tran H, Gu R, Lynch ED. Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hear Res. 2007 Apr;226(1-2):44-51. Epub 2006 Oct 6.</citation>
    <PMID>17030476</PMID>
  </reference>
  <reference>
    <citation>Lynch E, Kil J. Development of Ebselen, a Glutathione Peroxidase Mimic, for the Prevention and Treatment of Noise-Induced Hearing Loss. Semin Hear 2009; 30(1): 047-055</citation>
  </reference>
  <reference>
    <citation>Le Prell CG, Yang Q, Harris JG. Modification of digital music files for use in human temporary threshold shift studies. J Acoust Soc Am. 2011 Oct;130(4):EL142-6. doi: 10.1121/1.3630017.</citation>
    <PMID>21974483</PMID>
  </reference>
  <reference>
    <citation>Le Prell CG, Dell S, Hensley B, Hall JW 3rd, Campbell KC, Antonelli PJ, Green GE, Miller JM, Guire K. Digital music exposure reliably induces temporary threshold shift in normal-hearing human subjects. Ear Hear. 2012 Nov-Dec;33(6):e44-58. doi: 10.1097/AUD.0b013e31825f9d89.</citation>
    <PMID>22885407</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2011</study_first_posted>
  <last_update_submitted>August 26, 2014</last_update_submitted>
  <last_update_submitted_qc>August 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Temporary Auditory Threshold Shift</keyword>
  <keyword>Hearing Loss</keyword>
  <keyword>Deafness</keyword>
  <keyword>SPI-1005</keyword>
  <keyword>Ebselen</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ebselen</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 7, 2016</submitted>
    <returned>July 15, 2016</returned>
    <submitted>November 21, 2017</submitted>
    <returned>December 21, 2017</returned>
    <submitted>January 25, 2018</submitted>
    <returned>March 1, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

